Would be nice if a PR answered more questions than it raised.
Back in September 2023, the PR read "The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226) for ADAS-Cog13"
and now the PR reads " Over 48 weeks, blarcamesine significantly slowed clinical progression by 36.3% in the primary endpoint ADAS-Cog13 [LS mean ADAS-Cog13 difference of -2.027; P=0.008]"
Why the difference --- more importantly, what patients were dropped from the ITT or what parameters were changed in the MMRM/LSM in order to get different numbers. What is n. Are the new cohorts matched for entry severity? Is this the third or fourth different 'primary endpoint' method of analysis? Maybe the actual presentation will present . Better yet, show us the SAP.
Market Data 
Markets 
AI
